RxDoctor Payments DataLook up a doctor →

Joseph McEvoy, MD

Psychiatry · Augusta, GANPI 1962586859

Payments from drug & device makers

$631,229in general payments, 2019–2025

Across 575 payments — averaging $1097.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$315K
  • Teva Pharmaceuticals USA, Inc.$91K
  • Biogen$74K
  • Boehringer Ingelheim$72K
  • Neurocrine Biosciences, Inc.$46K
  • Takeda Pharmaceuticals U.S.A., Inc.$20K
  • plus $13K from 14 others
$4,998in research payments, 2019–2025

Across 1 payment — averaging $4998.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Teva Pharmaceuticals USA, Inc.$5K

What the payments were for

  • Consulting fees$16,37545%
  • Speaking & faculty fees$10,45029%
  • Travel & lodging$3,95711%
  • Food & beverage$5,66616%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$631,229 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$4,682
Medicare patients
25
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate48$92,374
Clozapine100$9,490
Aripiprazole18$1,939
Olanzapine80$1,144
Divalproex Sodium ErDivalproex Sodium17$989
Gabapentin91$740
Glycopyrrolate25$623
Desmopressin Acetate18$617
Risperidone37$579
Oxcarbazepine12$531
Clonazepam69$390
Lamotrigine63$390
Quetiapine Fumarate17$378
Duloxetine Hcl22$356
Metformin Hcl ErMetformin Hcl47$325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$186$92,37448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →